CPT® Code 86042

Acetylcholine receptor (AChR) antibodies are specific proteins that can be found in the bloodstream of individuals diagnosed with myasthenia gravis (MG), a rare neuromuscular disorder characterized by significant muscle weakness and fatigue. Myasthenia gravis can manifest in two primary forms: ocular myasthenia gravis, which primarily affects the muscles around the eyes, leading to symptoms such as drooping eyelids, double vision, and weakness in eye muscle function; and generalized myasthenia gravis, which can involve weakness in various muscle groups, including those in the neck, throat, and respiratory system. Patients with generalized MG may experience difficulties with chewing, swallowing, speaking, and may even face challenges in walking or breathing. It is noteworthy that approximately 15% of individuals with MG may only exhibit ocular symptoms. The presence of AChR antibodies disrupts the normal communication between nerves and muscles by interfering with the action of acetylcholine, a critical neurotransmitter responsible for transmitting signals from nerves to muscles. Specifically, blocking antibodies hinder acetylcholine from effectively binding to its receptors on muscle cells, which results in diminished muscle contraction and function. To diagnose the presence of these antibodies, a venous blood sample is collected, and semi-quantitative flow cytometry is employed for testing. A positive result for AChR antibodies can confirm a diagnosis of MG in symptomatic patients; however, it is important to note that elevated antibody levels may also be observed in individuals with thymoma, a type of tumor associated with the thymus gland. In clinical practice, it is estimated that 10%-15% of patients with MG may not test positive for AChR antibodies, necessitating further testing for other types of antibodies, such as muscle-specific kinase (MuSK) antibodies. A blocking antibody result exceeding 42% is interpreted as positive, while results ranging from 26% to 41% are deemed indeterminate, indicating the need for additional testing for modulating antibodies. Blocking antibodies represent the second most prevalent type of AChR antibody found in patients with generalized myasthenia gravis.